alog_pcfb {MBNMAtime} | R Documentation |
Studies of alogliptin for lowering blood glucose concentration in patients with type II diabetes
Description
A dataset from a systematic review of Randomised-Controlled Trials (RCTs) comparing different doses of alogliptin with placebo (Langford et al. 2016). The systematic review was simply performed and was intended to provide data to illustrate a statistical methodology rather than for clinical inference. Alogliptin is a treatment aimed at reducing blood glucose concentration in type II diabetes. The outcome is continuous, and aggregate data responses correspond to the mean change in HbA1c from baseline to follow-up. The dataset includes 14 Randomised-Controlled Trials (RCTs), comparing 5 different doses of alogliptin with placebo, leading to 6 different treatments (combination of dose and agent) within the network.
Usage
alog_pcfb
Format
A data frame in long format (one row per arm and study), with 46 rows and 9 variables:
-
studyID
Study identifiers -
clinicaltrialGov_ID
The clinicaltrial.gov ID code -
agent
Character data indicating the agent to which participants were randomised -
dose
Numeric data indicating the standardised dose received -
treatment
Character data indicating the treatment (combination of agent and dose) to which participants were randomised -
time
Numeric data indicating the time at which the observation was measured (given in weeks) -
y
Numeric data indicating the mean change from baseline in blood glucose concentration (mg/dL) in a study arm -
se
Numeric data indicating the standard error for the mean change from baseline in blood glucose concentration (mg/dL) in a study arm -
n
Numeric data indicating the number in each arm at each follow-up time
Details
alog_pcfb
is a data frame in long format (one row per observation, arm and study),
with the variables studyID
, clinicaltrialGov_ID
, agent
, dose
, treatment
, time
, y
, se
, and n
.
References
Langford O, Aronson JK, van Valkenhoef G, Stevens RJ (2016). “Methods for meta-analysis of pharmacodynamic dose-response data with application to multi-arm studies of alogliptin.” Stat Methods Med Res. ISSN 1477-0334 (Electronic) 0962-2802 (Linking), doi:10.1177/0962280216637093, https://pubmed.ncbi.nlm.nih.gov/26994216/.